To Örebro University

oru.seÖrebro University Publications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 68) Show all publications
Backman, H. E., Karefylakis, C., Schwarcz, E., Magnuson, A., Branzell, I., Nolan, C. J. & Simmons, D. (2024). Diagnosis of Gestational Diabetes Mellitus: How Should We Measure Glucose?. Diabetes Care, Article ID dc231557.
Open this publication in new window or tab >>Diagnosis of Gestational Diabetes Mellitus: How Should We Measure Glucose?
Show others...
2024 (English)In: Diabetes Care, ISSN 0149-5992, E-ISSN 1935-5548, article id dc231557Article in journal, Editorial material (Refereed) Epub ahead of print
Place, publisher, year, edition, pages
American Diabetes Association, 2024
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-111024 (URN)10.2337/dc23-1557 (DOI)38241086 (PubMedID)
Funder
Region Örebro County, OLL- 970566; OLL-942177
Note

This study was funded by Region€Orebro Research Committee (grants Dnr OLL-970566 and OLL-942177). This study was alsosupported by the National Health and Medi-cal Research Council (1104231).

Available from: 2024-02-01 Created: 2024-02-01 Last updated: 2024-02-01Bibliographically approved
Harreiter, J., Simmons, D., Immanuel, J., Hague, B., Teede, H., Cheung, N. W., . . . Kautzky-Willer, A. (2023). Behandlung von früh diagnostiziertem Gestationsdiabetes mellitus vor der 20. Schwangerschaftswoche: [Treatment of early diagnosed Gestational Diabetes mellitus before the 20th Week of Pregnancy]. Paper presented at 51. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Österreich, November 16-18, 2023. Wiener Klinische Wochenschrift, 135(Suppl. 7), S762-S762, Article ID 19.
Open this publication in new window or tab >>Behandlung von früh diagnostiziertem Gestationsdiabetes mellitus vor der 20. Schwangerschaftswoche: [Treatment of early diagnosed Gestational Diabetes mellitus before the 20th Week of Pregnancy]
Show others...
2023 (German)In: Wiener Klinische Wochenschrift, ISSN 0043-5325, E-ISSN 1613-7671, Vol. 135, no Suppl. 7, p. S762-S762, article id 19Article in journal, Meeting abstract (Other academic) Published
Abstract [de]

Einleitung: Bei Diagnose eines Gestationsdiabetes (GDM) vor der 20.Schwangerschaftswoche (SSW) wird leitliniengemäß eine Therapie begonnen. Für diese Praxis liegt keine Evidenz vor, die eine Verbesserung der Gesundheit von Mutter oder Nachkommen bei GDM-Behandlung in der frühen Schwangerschaft belegt.

Methoden: Frauen mit einem Risikofaktor für GDM wurden zwischen 4.−20.SSW bei Vorliegen einer GDM Diagnose nach WHO 2013 Kriterien randomisiert einer Behandlungsgruppe oder einer Kontrollgruppe zugeordnet. Die Behandlungs-gruppe erhielt sofortige GDM Behandlung, während die Kontrollgruppe je nach Ergebnissen eines erneuten oralen Glukosetoleranztests (OGTT) in der 24.−28.SSW eine verschobene oder keine Behandlung erhielt. Die Studie hatte drei primäre Endpunkte: eine Kombination ungünstiger neonataler Ereignisse (Geburt <37.SSW, Geburtstrauma, Geburtsgewicht ≥4500 g, RDS, Phototherapie, Totgeburt/neonataler Tod oder Schulterdystokie), schwangerschaftsbedingte Hypertonieerkrankungen (Präeklampsie, Eklampsie, gestationsbedingter Bluthochdruck) und neonatale fettfreie Körpermasse.

Ergebnisse: Insgesamt wurden 802 Frauen randomisiert (406 Sofortbehandlung, 396 Kontrollgruppe). Die Erstvisite fand durchschnittlich in der 15,6 ± 2,5 SSW statt. Der neonatale Kombinationsendpunkt trat bei 94/378 Frauen (24,9 %) bei sofortiger Behandlung und bei 113/370 Frauen (30,5 %) in der Kontrollgruppe auf (adj. Risikounterschied −5,6 %;95 % KI,–10,1;−1,2, RR 0,82;0,68-0,98). Schwangerschaftsbedingter Bluthochdruck trat bei 40/378 Frauen (10,6 %) bei sofortiger Behandlung und bei 37/372 Frauen (9,9 %) in der Kontrollgruppe auf (0,7 %,95 % KI,–1,6;2,9, RR 1.08;0.85–1.38). Die fettfreie Körpermasse der Neugeborenen betrug 2,86 kg bei sofortiger Behandlung und 2,91 kg in der Kontrollgruppe (−0,04 kg; 95 % KI,–0,09;0,02). Untergruppenanalysen zeigten eine stärkere Wirkung der Intervention auf neonatale Ergebnisse bei Frauen mit höheren Blutzuckerwerten und bei OGTT Durchführung vor der 14.SSW.

Schlussfolgerung: Die sofortige Behandlung von Gestationsdiabetes vor der 20.SSW führte zu einer geringeren Häufigkeit ungünstiger neonataler Ergebnisse im Vergleich zu späterem Behandlungsbeginn.

Place, publisher, year, edition, pages
Springer, 2023
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-111275 (URN)001126077800020 ()
Conference
51. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Österreich, November 16-18, 2023
Available from: 2024-02-02 Created: 2024-02-02 Last updated: 2024-02-02Bibliographically approved
Fadl, H., Saeedi, M., Magnuson, A., Patil, S., Simmons, D., Schwarcz, E., . . . Montgomery, S. (2023). Changing diagnostic criteria for gestational diabetes (CDC4G) in Sweden: a stepped wedge cluster randomised controlled trial. In: : . Paper presented at 55th DPSG annual meeting 2023, Poznan, Polen, 7-10 September, 2023.. (1)
Open this publication in new window or tab >>Changing diagnostic criteria for gestational diabetes (CDC4G) in Sweden: a stepped wedge cluster randomised controlled trial
Show others...
2023 (English)Conference paper, Oral presentation only (Other academic)
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-109825 (URN)
Conference
55th DPSG annual meeting 2023, Poznan, Polen, 7-10 September, 2023.
Available from: 2023-11-22 Created: 2023-11-22 Last updated: 2024-01-02Bibliographically approved
Diurlin, S., Patil, S., Lindblad, U., Daka, B., Hellgren, M. I. & Backman, H. (2023). Gestational diabetes diagnosis in the Swedish Pregnancy Register. Paper presented at 59th EASD Annual Meeting of the European Association for the Study of Diabetes, Hamburg, Germany, October 2-6, 2023. Diabetologia, 66(Suppl. 1), S264-S265, Article ID 521.
Open this publication in new window or tab >>Gestational diabetes diagnosis in the Swedish Pregnancy Register
Show others...
2023 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 66, no Suppl. 1, p. S264-S265, article id 521Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Background and aims: The Changing Diagnostic Criteria for Gestational Diabetes (GDM) study (CDC4G) is a stepped wedged randomized controlled trial in Sweden on the effects of introducing the 2013 WHO criteriaf or diagnosing GDM. Almost all Swedish pregnancies are registered in the Swedish Pregnancy Register (SPR). The CDC4G study provides a unique opportunity to validate the GDM diagnosis in the SPR. We aim to 1) validate the diagnosis of GDM in the SPR using the laboratory values from the oral glucose tolerance tests (OGTT) in the CDC4G study as the gold standard; 2) explore effects of change in diagnostic criteria on validity and prevalence of the diagnosis of GDM. Secondary aim is to investigate whether incident GDM diagnoses during pregnancy are recorded by the midwife when entering the follow-up postpartum registration in the SPR.

Materials and methods: Data from the SPR were compared with data from the CDC4G eCRF (gold standard measurements: venous OGTT values fasting, 1-h and 2-h) among 6080 screened individuals in 2018. We also investigated if the GDM diagnosis, set at the maternity ward was registered by the midwives at the postpartum follow-up (SPR tickbox). We present the sensitivity, specificity, positive (PPV) and negative (NPV) predictive value for each question. The study was approved by the Uppsala-Örebro regional Ethical Review board (2016/487), and by the Swedish Ethical Review Authority (2019/02148, 2020/02856, 2021/02055).

Results: Validating the ICD-code GDM (O24.4) in the Swedish Pregnancy Register resulted in 84.7% sensitivity, 96.7% specificity, PPV of 91.8%, and NPV of 93.5%. The prevalence of the GDM diagnosis more than tripled using the new criteria (Table 1). Both the sensitivity and specificity of the follow-up postpartum registration of GDM were considerably lower than for the GDM ICD-code, 76.6% and 87.6%, respectively. There were some minor differences in the accuracy of the registration before and after the switch to the new criteria for GDM, see table 1.

Conclusion: The coding of GDM in clinical practice, that is transferred to the SPR needs to be improved. We recommend researchers to use data based on ICD coding, instead of manually entered SPR data, until the quality of the variable has improved.

Place, publisher, year, edition, pages
Springer, 2023
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-109779 (URN)001065473000520 ()
Conference
59th EASD Annual Meeting of the European Association for the Study of Diabetes, Hamburg, Germany, October 2-6, 2023
Available from: 2023-11-21 Created: 2023-11-21 Last updated: 2023-11-21Bibliographically approved
SIMMONS, D., IMMANUEL, J., WAH CHEUNG, N., HAGUE, W., TEEDE, H., NOLAN, C. J., . . . HARREITER, J. (2023). Neonatal Outcomes in Early and Incident Gestational Diabetes Mellitus: Are They Normalized with Treatment from 24–28 Weeks’ Gestation?. Paper presented at ADA-Diabetes Congress 2023, San Diego, USA, June 23-26, 2023. Diabetes, 72(Supplement 1), Article ID 281-OR.
Open this publication in new window or tab >>Neonatal Outcomes in Early and Incident Gestational Diabetes Mellitus: Are They Normalized with Treatment from 24–28 Weeks’ Gestation?
Show others...
2023 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 72, no Supplement 1, article id 281-ORArticle in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
American Diabetes Association, 2023
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-107008 (URN)10.2337/db23-281-or (DOI)001052854601087 ()
Conference
ADA-Diabetes Congress 2023, San Diego, USA, June 23-26, 2023
Available from: 2023-07-06 Created: 2023-07-06 Last updated: 2023-12-07Bibliographically approved
Hildén, K., Magnuson, A., Montgomery, S., Schwarcz, E., Hanson, U., Simmons, D. & Backman, H. (2023). Previous pre-eclampsia, gestational diabetes mellitus and the risk of cardiovascular disease: A nested case-control study in Sweden. British Journal of Obstetrics and Gynecology, 130(10), 1209-1216
Open this publication in new window or tab >>Previous pre-eclampsia, gestational diabetes mellitus and the risk of cardiovascular disease: A nested case-control study in Sweden
Show others...
2023 (English)In: British Journal of Obstetrics and Gynecology, ISSN 1470-0328, E-ISSN 1471-0528, Vol. 130, no 10, p. 1209-1216Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: Pre-eclampsia and gestational diabetes mellitus (GDM) are two common pregnancy complications that affect birth outcomes and are associated with a long-term risk of cardiovascular disease (CVD). The aims of this study were to investigate if the pre-eclampsia association with CVD is independent of GDM and modified by body mass index (BMI) or GDM. DESIGN: Case-control study.

SETTING: Sweden.

POPULATION: Cases were women with a first CVD event between 1991 and 2008 and a previous pregnancy who were matched with controls without CVD (1:5) by year of birth, age and region of birth. METHODS: Conditional logistic regression was used to evaluate the associations of GDM, pre-eclampsia and maternal BMI with CVD adjusted for potential confounders and effect modifications with interaction tests.

MAIN OUTCOME MEASURES: CVD.

RESULTS: There were 2639 cases and 13 310 controls with complete data. Pre-eclampsia and GDM were independent risk factors for CVD (adjusted odds ratio [aOR] 2.59, 95% CI 2.12-3.17 and aOR 1.47, 95% CI 1.04-2.09, respectively). After stratifying by maternal BMI, the adjusted association of pre-eclampsia with CVD did not differ notably between BMI groups: normal weight (aOR 2.65, 95% CI 1.90-3.69), overweight (aOR 2.67, 95% CI 1.52-4.68) and obesity (aOR 3.03, 95% CI 0.74-12.4). Similar findings were seen when stratifying on GDM/non-GDM.

CONCLUSIONS: Pre-eclampsia and GDM are independent risk factors for later CVD and having both during pregnancy is a major risk factor for later CVD. The association between pre-eclampsia and CVD is not modified by BMI. Effective CVD preventive programs for high-risk women are urgently needed in order to improve women's long-term health.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
Keywords
Cardiovascular disease, gestational diabetes, hypertension, morbidity, mortality, overweight, pre-eclampsia, pregnancy, smoking
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-105221 (URN)10.1111/1471-0528.17454 (DOI)000959281800001 ()36974033 (PubMedID)2-s2.0-85151416172 (Scopus ID)
Funder
Region Örebro County, OLL 939071 OLL 961321
Available from: 2023-03-30 Created: 2023-03-30 Last updated: 2023-12-08Bibliographically approved
Skogsdal, Y. R., Karlsson, J., Tydén, T., Patil, S. & Backman, H. (2023). The association of smoking, use of snuff, and preconception alcohol consumption with spontaneous abortion: A population-based cohort study. Acta Obstetricia et Gynecologica Scandinavica, 102(1), 15-24
Open this publication in new window or tab >>The association of smoking, use of snuff, and preconception alcohol consumption with spontaneous abortion: A population-based cohort study
Show others...
2023 (English)In: Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, E-ISSN 1600-0412, Vol. 102, no 1, p. 15-24Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: It is unclear whether tobacco in early pregnancy and alcohol use preceding pregnancy are associated with spontaneous abortion. The purpose was to investigate if use of tobacco and/or alcohol is associated with spontaneous abortion among women attending antenatal care, and if age and body mass index (BMI) attenuate the risk.

MATERIAL AND METHODS: A population-based cohort study based on data from the Swedish Pregnancy Register. All pregnant women having had the first antenatal visit from January 2014 to July 2018 were included (n = 525 604). The register had information about smoking and use of snuff before and in early pregnancy, as well as data on alcohol habits before pregnancy, measured by the Alcohol Use Disorders Identification Test (AUDIT), a validated questionnaire. Logistic regression analysis was used to estimate the association between lifestyle factors and spontaneous abortion, and multiple imputation was used to impute missing data.

RESULTS: In total, 34 867 (6.6%) pregnancies ended in a spontaneous abortion after the first visit to maternal health care. At the first maternal healthcare visit, daily smoking was reported by 24 214 (5.1%), and 6403 (1.2%) used snuff. For 19 837 (4.2%) women, a high alcohol score was reported for the year preceding pregnancy. After adjusting for potential confounders and multiple imputation, use of tobacco was associated with spontaneous abortion; smoking 1-9 cigarettes/day (adjusted odds ratio [aOR] 1.11, 95% confidence interval [CI] 1.04-1.18), smoking 10 or more cigarettes/day (aOR 1.12, 95% CI 1.-1.26), and use of snuff (aOR 1.20, 95% CI 1.06-1.37). Higher AUDIT scores were not significantly associated with spontaneous abortion (AUDIT 6-9: aOR 1.03, 95% CI 0.97-1.10 and AUDIT 10 or more: aOR 1.07, 95% CI 0.94-1.22). Increasing maternal age showed the highest risk of spontaneous abortion from the age of 35, and BMI of 30 kg/m2 or more increased the risk. There were interactions between different lifestyle factors associated with spontaneous abortion that could either increase or decrease the risk of spontaneous abortion.

CONCLUSIONS: Smoking and use of snuff were associated with an increased risk of spontaneous abortion. The AUDIT scores preceding pregnancy were not associated with an increased risk of spontaneous abortion, which contradicts the results from previous studies.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
Keywords
AUDIT, alcohol, lifestyle factors, oral tobacco, pregnancy, smoking, snuff, spontaneous abortion
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:oru:diva-101766 (URN)10.1111/aogs.14470 (DOI)000866149300001 ()36222196 (PubMedID)2-s2.0-85139712960 (Scopus ID)
Funder
Region Örebro County, OLL 836701 OLL 929557 OLL-837211
Available from: 2022-10-13 Created: 2022-10-13 Last updated: 2024-01-02Bibliographically approved
Simmons, D., Immanuel, J., Hague, W. M., Teede, H., Nolan, C. J., Peek, M. J., . . . Cheung, N. W. (2023). Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. New England Journal of Medicine, 388(23), 2132-2144
Open this publication in new window or tab >>Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy
Show others...
2023 (English)In: New England Journal of Medicine, ISSN 0028-4793, E-ISSN 1533-4406, Vol. 388, no 23, p. 2132-2144Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Whether treatment of gestational diabetes before 20 weeks' gestation improves maternal and infant health is unclear.

METHODS: We randomly assigned, in a 1:1 ratio, women between 4 weeks' and 19 weeks 6 days' gestation who had a risk factor for hyperglycemia and a diagnosis of gestational diabetes (World Health Organization 2013 criteria) to receive immediate treatment for gestational diabetes or deferred or no treatment, depending on the results of a repeat oral glucose-tolerance test [OGTT] at 24 to 28 weeks' gestation (control). The trial included three primary outcomes: a composite of adverse neonatal outcomes (birth at <37 weeks' gestation, birth trauma, birth weight of ≥4500 g, respiratory distress, phototherapy, stillbirth or neonatal death, or shoulder dystocia), pregnancy-related hypertension (preeclampsia, eclampsia, or gestational hypertension), and neonatal lean body mass.

RESULTS: A total of 802 women underwent randomization; 406 were assigned to the immediate-treatment group and 396 to the control group; follow-up data were available for 793 women (98.9%). An initial OGTT was performed at a mean (±SD) gestation of 15.6±2.5 weeks. An adverse neonatal outcome event occurred in 94 of 378 women (24.9%) in the immediate-treatment group and in 113 of 370 women (30.5%) in the control group (adjusted risk difference, -5.6 percentage points; 95% confidence interval [CI], -10.1 to -1.2). Pregnancy-related hypertension occurred in 40 of 378 women (10.6%) in the immediate-treatment group and in 37 of 372 women (9.9%) in the control group (adjusted risk difference, 0.7 percentage points; 95% CI, -1.6 to 2.9). The mean neonatal lean body mass was 2.86 g in the immediate-treatment group and 2.91 g in the control group (adjusted mean difference, -0.04 g; 95% CI, -0.09 to 0.02). No between-group differences were observed with respect to serious adverse events associated with screening and treatment.

CONCLUSIONS: Immediate treatment of gestational diabetes before 20 weeks' gestation led to a modestly lower incidence of a composite of adverse neonatal outcomes than no immediate treatment; no material differences were observed for pregnancy-related hypertension or neonatal lean body mass. (Funded by the National Health and Medical Research Council and others; TOBOGM Australian New Zealand Clinical Trials Registry number, ACTRN12616000924459.).

Place, publisher, year, edition, pages
Massachusetts Medical Society, 2023
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-105864 (URN)10.1056/NEJMoa2214956 (DOI)000984868200001 ()37144983 (PubMedID)2-s2.0-85163238211 (Scopus ID)
Available from: 2023-05-09 Created: 2023-05-09 Last updated: 2023-10-26Bibliographically approved
Fadl, H., Patil, S., Wikström, A.-K., Jansson, S. P. O., Sengpiel, V., Berntorp, K., . . . SIMMONS, D. (2022). Association of GDM Risk Factors with Glucose at Diagnosis and Treatment in Sweden. Paper presented at ADA- American Diabetes Association 82nd Scientific Session, New Orleans, USA, June 3, 2022. Diabetes, 71(Supplement_1), Article ID 1039-P.
Open this publication in new window or tab >>Association of GDM Risk Factors with Glucose at Diagnosis and Treatment in Sweden
Show others...
2022 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 71, no Supplement_1, article id 1039-PArticle in journal, Meeting abstract (Refereed) Published
Place, publisher, year, edition, pages
American Diabetes Association, 2022
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-100807 (URN)10.2337/db22-1039-p (DOI)000854899301530 ()
Conference
ADA- American Diabetes Association 82nd Scientific Session, New Orleans, USA, June 3, 2022
Available from: 2022-08-24 Created: 2022-08-24 Last updated: 2024-01-02Bibliographically approved
Valgeirsdóttir, I. R., Hanson, U., Schwarcz, E., Simmons, D. & Backman, H. (2022). Diet-Treated Gestational Diabetes Mellitus Is an Underestimated Risk Factor for Adverse Pregnancy Outcomes: A Swedish Population-Based Cohort Study. Nutrients, 14(16), Article ID 3364.
Open this publication in new window or tab >>Diet-Treated Gestational Diabetes Mellitus Is an Underestimated Risk Factor for Adverse Pregnancy Outcomes: A Swedish Population-Based Cohort Study
Show others...
2022 (English)In: Nutrients, E-ISSN 2072-6643, Vol. 14, no 16, article id 3364Article in journal (Refereed) Published
Abstract [en]

In Sweden, diet-treated gestational diabetes mellitus (GDM) pregnancies have been managed as low risk. The aim was to evaluate the risk of adverse perinatal outcomes among women with diet-treated GDM compared with the background population and with insulin-treated GDM. This is a population-based cohort study using national register data between 1998 and 2012, before new GDM management guidelines and diagnostic criteria in Sweden were introduced. Singleton pregnancies (n = 1,455,580) without pregestational diabetes were included. Among 14,242 (1.0%) women diagnosed with GDM, 8851 (62.1%) were treated with diet and 5391 (37.9%) with insulin. In logistic regression analysis, the risk was significantly increased in both diet- and insulin-treated groups (vs. background) for large-for-gestational-age newborns, preeclampsia, cesarean section, birth trauma and preterm delivery. The risk was higher in the insulin-treated group (vs. diet) for most outcomes, but perinatal mortality rates neither differed between treatment groups nor compared to the background population. Diet as a treatment for GDM did not normalize pregnancy outcomes. Pregnancies with diet-treated GDM should therefore not be considered as low risk. Whether changes in surveillance and treatment improve outcomes needs to be evaluated.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
Diabetes in pregnancy, diet therapy, gestational diabetes, insulin, pregnancy outcomes
National Category
Endocrinology and Diabetes Obstetrics, Gynecology and Reproductive Medicine
Identifiers
urn:nbn:se:oru:diva-100868 (URN)10.3390/nu14163364 (DOI)000845938600001 ()36014870 (PubMedID)2-s2.0-85136698018 (Scopus ID)
Funder
Region Örebro County, OLL-690671 OLL-967491
Available from: 2022-08-26 Created: 2022-08-26 Last updated: 2023-08-28Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-2691-7525

Search in DiVA

Show all publications